Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01582672
Title Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Argos Therapeutics
Indications

renal cell carcinoma

Therapies

Sunitinib

Age Groups: adult
Covered Countries USA | ITA | ESP | CAN


No variant requirements are available.